β‐glucan as a new tool in vaccine development

Vaccination constitutes one of the major breakthroughs in human medicine. At the same time, development of more immunogenic vaccine alternatives to using aluminium‐based adjuvants is one of the most important phases of vaccination development. Among different sources of carbohydrate polymers, includ...

Full description

Saved in:
Bibliographic Details
Published inScandinavian journal of immunology Vol. 91; no. 2; pp. e12833 - n/a
Main Authors Vetvicka, Vaclav, Vannucci, Luca, Sima, Petr
Format Journal Article
LanguageEnglish
Published England Wiley Subscription Services, Inc 01.02.2020
Subjects
Adjuvants
Adjuvants, Immunologic
Aluminum
Animals
Antigen Presentation
Antigen-presenting cells
Antigens
beta-Glucans - immunology
beta-Glucans - therapeutic use
cancer
diseases
Drug Delivery Systems - methods
experimental animals
Glucans
Humans
Hydrogels
Hydrogels - therapeutic use
Immunization
Immunogenicity
Oligodeoxyribonucleotides
Oligonucleotides
processes
subject
Vaccination
Vaccine development
Vaccines
Vaccines - immunology
β-Glucan
diseases
experimental animals
processes
cancer
subject
vaccination
Online AccessGet full text

Cover

Abstract Vaccination constitutes one of the major breakthroughs in human medicine. At the same time, development of more immunogenic vaccine alternatives to using aluminium‐based adjuvants is one of the most important phases of vaccination development. Among different sources of carbohydrate polymers, including plants, microbes and synthetic sources tested, glucans were found to be the most promising vaccine adjuvant, as they alone stimulate various immune reactions including antibody production without any negative side effects. The use of glucan particles as a delivery system is a viable option based on the documented efficient antigen loading and receptor‐targeted uptake in antigen‐presenting cells. In addition to particles, soluble glucans can be used as novel hydrogels or as direct immunocyte‐targeting delivery systems employing novel complexes with oligodeoxynucleotides. This review focuses on recent advances in glucan‐based vaccine development from glucan‐based conjugates to a glucan‐based delivery and adjuvant platform.
AbstractList Vaccination constitutes one of the major breakthroughs in human medicine. At the same time, development of more immunogenic vaccine alternatives to using aluminium‐based adjuvants is one of the most important phases of vaccination development. Among different sources of carbohydrate polymers, including plants, microbes and synthetic sources tested, glucans were found to be the most promising vaccine adjuvant, as they alone stimulate various immune reactions including antibody production without any negative side effects. The use of glucan particles as a delivery system is a viable option based on the documented efficient antigen loading and receptor‐targeted uptake in antigen‐presenting cells. In addition to particles, soluble glucans can be used as novel hydrogels or as direct immunocyte‐targeting delivery systems employing novel complexes with oligodeoxynucleotides. This review focuses on recent advances in glucan‐based vaccine development from glucan‐based conjugates to a glucan‐based delivery and adjuvant platform.
Vaccination constitutes one of the major breakthroughs in human medicine. At the same time, development of more immunogenic vaccine alternatives to using aluminium-based adjuvants is one of the most important phases of vaccination development. Among different sources of carbohydrate polymers, including plants, microbes and synthetic sources tested, glucans were found to be the most promising vaccine adjuvant, as they alone stimulate various immune reactions including antibody production without any negative side effects. The use of glucan particles as a delivery system is a viable option based on the documented efficient antigen loading and receptor-targeted uptake in antigen-presenting cells. In addition to particles, soluble glucans can be used as novel hydrogels or as direct immunocyte-targeting delivery systems employing novel complexes with oligodeoxynucleotides. This review focuses on recent advances in glucan-based vaccine development from glucan-based conjugates to a glucan-based delivery and adjuvant platform.Vaccination constitutes one of the major breakthroughs in human medicine. At the same time, development of more immunogenic vaccine alternatives to using aluminium-based adjuvants is one of the most important phases of vaccination development. Among different sources of carbohydrate polymers, including plants, microbes and synthetic sources tested, glucans were found to be the most promising vaccine adjuvant, as they alone stimulate various immune reactions including antibody production without any negative side effects. The use of glucan particles as a delivery system is a viable option based on the documented efficient antigen loading and receptor-targeted uptake in antigen-presenting cells. In addition to particles, soluble glucans can be used as novel hydrogels or as direct immunocyte-targeting delivery systems employing novel complexes with oligodeoxynucleotides. This review focuses on recent advances in glucan-based vaccine development from glucan-based conjugates to a glucan-based delivery and adjuvant platform.
Author Vannucci, Luca
Sima, Petr
Vetvicka, Vaclav
Author_xml – sequence: 1
  givenname: Vaclav
  orcidid: 0000-0002-3227-2938
  surname: Vetvicka
  fullname: Vetvicka, Vaclav
  email: Vaclav.vetvicka@louisville.edu
  organization: University of Louisville
– sequence: 2
  givenname: Luca
  surname: Vannucci
  fullname: Vannucci, Luca
  organization: Institute of Microbiology
– sequence: 3
  givenname: Petr
  surname: Sima
  fullname: Sima, Petr
  organization: Institute of Microbiology
BackLink https://www.ncbi.nlm.nih.gov/pubmed/31544248$$D View this record in MEDLINE/PubMed
BookMark eNp1kDtOAzEURS0URD5QsAE0Eg0Uk_gzH0-JIj5BkSiA2nJsD3LkscN4JlE6lsBaWAiLYCU4JDQRvOY151y9d_ugY51VAJwiOERhRn6uhwhTQg5AD5EsjQmkpAN6kEAYF0medkHf-zmEiOCcHIEuQWmS4IT2APz8-Hp7fzGt4DbiPuKRVauocc5E2kZLLoS2KpJqqYxbVMo2x-Cw5Mark90egOeb66fxXTx9uJ2Mr6axIJSSOM0KgRAUaCaxwiXEshCKzmCOCUbhvDTFFBMl85JTCWmWZ0ggkctSBjMpEBmAi23uonavrfINq7QXyhhulWs9w7jIEIabnwbgfA-du7a24TqGCSkSlBRpGqizHdXOKiXZotYVr9fst4sAjLaAqJ33tSqZ0A1vtLNNzbVhCLJN2yy0zX7aDsblnvEb-he7S19po9b_g-zxfrI1vgFQ6ovx
CitedBy_id crossref_primary_10_1007_s00262_021_03136_7
crossref_primary_10_1021_acsami_1c12366
crossref_primary_10_1007_s10695_023_01292_4
crossref_primary_10_7774_cevr_2024_13_4_338
crossref_primary_10_3389_fimmu_2021_634402
crossref_primary_10_3390_nu13082791
crossref_primary_10_3390_vaccines10040620
crossref_primary_10_1080_17425247_2022_2152791
crossref_primary_10_4028_p_ns8294
crossref_primary_10_1016_j_carbpol_2023_121163
crossref_primary_10_1016_j_ijbiomac_2021_04_069
crossref_primary_10_1021_acsami_3c03528
crossref_primary_10_3390_vaccines12121428
crossref_primary_10_3389_fnut_2021_646988
crossref_primary_10_3390_encyclopedia1030064
crossref_primary_10_1016_j_carbpol_2023_121367
crossref_primary_10_1042_BSR20230041
crossref_primary_10_1039_D2BM00316C
crossref_primary_10_1016_j_carbpol_2024_121904
crossref_primary_10_3390_cancers14235802
crossref_primary_10_1016_j_xphs_2020_11_011
crossref_primary_10_32900_2312_8402_2024_132_171_182
crossref_primary_10_1016_j_aquaculture_2021_736805
crossref_primary_10_3389_fbioe_2023_1095926
crossref_primary_10_1128_IAI_00607_20
crossref_primary_10_3390_ijms25189914
crossref_primary_10_1002_tcr_202100059
crossref_primary_10_3390_vaccines11071232
crossref_primary_10_1016_j_ijbiomac_2021_02_087
crossref_primary_10_3390_nu13082683
crossref_primary_10_1016_j_carres_2024_109245
crossref_primary_10_1016_j_ijpharm_2024_123996
crossref_primary_10_1021_acs_chemrev_0c01338
crossref_primary_10_3389_fbioe_2021_702173
crossref_primary_10_3390_cancers12010155
crossref_primary_10_3390_vaccines9010001
crossref_primary_10_3390_vaccines12010026
crossref_primary_10_1016_j_fsi_2021_09_003
crossref_primary_10_1111_imb_12900
crossref_primary_10_3390_ijms22020825
crossref_primary_10_1016_j_ccr_2022_214788
crossref_primary_10_3390_jof6040356
crossref_primary_10_3390_ijms23063156
crossref_primary_10_1016_j_ijbiomac_2022_11_003
crossref_primary_10_1016_j_ijbiomac_2023_123617
crossref_primary_10_1007_s13346_024_01694_8
crossref_primary_10_1080_21645515_2021_1880210
crossref_primary_10_1016_j_procbio_2024_09_011
crossref_primary_10_1016_j_jconrel_2023_09_010
crossref_primary_10_1002_aro2_96
crossref_primary_10_1016_j_livsci_2023_105289
Cites_doi 10.1615/CritRevTherDrugCarrierSyst.v26.i1.20
10.1016/j.vetimm.2013.10.004
10.1099/00222615-23-4-363
10.1016/0162-3109(83)90046-2
10.1016/0192-0561(92)90007-8
10.1016/j.imlet.2004.02.006
10.1111/j.1462-5822.2008.01188.x
10.1002/jsfa.8754
10.2527/1995.73113341x
10.1038/s41417-018-0033-2
10.1016/j.carbpol.2014.04.025
10.4103/1947-2714.120792
10.5582/ddt.2015.01025
10.1016/j.carbpol.2017.10.030
10.3109/02652048.2015.1073392
10.1016/j.imlet.2004.10.020
10.1016/j.jconrel.2015.10.025
10.1021/acs.biomac.6b01855
10.1128/IAI.40.3.1038-1043.1983
10.1016/0192-0561(90)90105-V
10.1128/mBio.00164-10
10.1248/cpb.39.1606
10.1080/00034983.1985.11811908
10.1016/j.ijbiomac.2016.06.057
10.1016/j.ijbiomac.2014.09.008
10.7164/antibiotics.45.1778
10.1016/j.jconrel.2013.09.007
10.1081/LPR-120004792
10.1016/j.coi.2012.03.014
10.1038/nm.3409
10.1128/mBio.01872-17
10.1016/j.copbio.2007.10.013
10.1016/j.fsi.2016.10.020
10.1002/eji.201546059
10.1016/j.biomaterials.2018.03.014
10.1016/0192-0561(85)90056-6
10.1128/IAI.64.6.2201-2205.1996
10.3109/00016489409128330
10.1016/j.carbpol.2017.02.030
10.4161/hv.28166
10.4049/jimmunol.156.3.1235
10.1016/0165-2478(93)90127-N
10.1016/j.ijbiomac.2014.05.048
10.1056/NEJMra1204186
10.1016/j.carbpol.2012.01.054
10.1007/s00253-008-1618-8
10.1016/j.biotechadv.2015.05.010
10.2147/IJN.S101881
10.1016/0192-0561(89)90087-8
10.1111/j.1600-065X.2009.00793.x
10.1021/acs.bioconjchem.7b00159
10.1111/j.1365-3083.1990.tb02926.x
10.1007/s00262-002-0321-3
10.1016/S0264-410X(96)00266-6
10.1046/j.1525-1373.1999.d01-86.x
10.1016/j.jconrel.2006.08.013
10.1016/S0008-8749(03)00061-3
10.1016/S1359-6446(05)03536-1
10.1021/acs.bioconjchem.6b00675
10.1051/parasite/1988636398
10.1016/j.biomaterials.2017.04.035
10.1016/S0192-0561(98)00007-1
10.1099/jmm.0.000138
10.1128/CVI.00463-13
10.3109/08923979309025996
10.1016/j.jconrel.2011.01.026
10.1046/j.1472-765X.2002.01201.x
10.4049/jimmunol.135.5.3388
10.1007/BF00531635
10.1016/j.fsi.2012.04.009
10.1038/nature26000
10.1016/j.ijpharm.2017.11.009
10.1016/S1074-7613(03)00233-4
10.1080/15476910802019045
10.1155/2012/831486
10.1016/0192-0561(92)90028-J
10.1038/srep10687
10.1007/978-1-4939-7104-6_11
10.1007/82_2011_140
10.1042/BJ20110352
10.4049/jimmunol.163.6.3045
10.4049/jimmunol.169.7.3876
10.1016/j.vaccine.2015.03.096
10.1128/IAI.00086-09
10.3109/08820131003680369
10.1016/j.carbpol.2013.10.078
10.1016/j.vaccine.2015.04.099
ContentType Journal Article
Copyright 2019 The Scandinavian Foundation for Immunology
2019 The Scandinavian Foundation for Immunology.
Copyright © 2020 The Scandinavian Foundation for Immunology
Copyright_xml – notice: 2019 The Scandinavian Foundation for Immunology
– notice: 2019 The Scandinavian Foundation for Immunology.
– notice: Copyright © 2020 The Scandinavian Foundation for Immunology
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QP
7QR
7T5
7TK
7U9
8FD
FR3
H94
K9.
M7N
NAPCQ
P64
7X8
DOI 10.1111/sji.12833
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Calcium & Calcified Tissue Abstracts
Chemoreception Abstracts
Immunology Abstracts
Neurosciences Abstracts
Virology and AIDS Abstracts
Technology Research Database
Engineering Research Database
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Algology Mycology and Protozoology Abstracts (Microbiology C)
Nursing & Allied Health Premium
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Nursing & Allied Health Premium
Virology and AIDS Abstracts
Technology Research Database
Algology Mycology and Protozoology Abstracts (Microbiology C)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Chemoreception Abstracts
Immunology Abstracts
Engineering Research Database
Calcium & Calcified Tissue Abstracts
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitleList Nursing & Allied Health Premium

CrossRef
MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 1365-3083
EndPage n/a
ExternalDocumentID 31544248
10_1111_sji_12833
SJI12833
Genre reviewArticle
Journal Article
Review
GrantInformation_xml – fundername: Institutional grants RVO
  funderid: 61388971; ARPA Foundation; Unicredit Bank
– fundername: Institutional grants RVO
  grantid: Unicredit Bank
– fundername: Institutional grants RVO
  grantid: 61388971
– fundername: Institutional grants RVO
  grantid: ARPA Foundation
GroupedDBID ---
-~X
.3N
.55
.GA
.GJ
.Y3
05W
0R~
10A
123
1OB
1OC
24P
2WC
31~
33P
36B
3O-
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5HH
5LA
5RE
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABDBF
ABEML
ABJNI
ABOCM
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFO
ACGFS
ACGOF
ACIWK
ACMXC
ACPOU
ACPRK
ACRPL
ACSCC
ACUHS
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZMN
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFNX
AFFPM
AFGKR
AFPWT
AFRAH
AFWVQ
AFZJQ
AHBTC
AHEFC
AHMBA
AIACR
AIAGR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
AOETA
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BAWUL
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DC6
DCZOG
DIK
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
E3Z
EAD
EAP
EAS
EBC
EBD
EBS
EBX
EJD
EMB
EMK
EMOBN
EPT
ESX
EX3
F00
F01
F04
F5P
FEDTE
FIJ
FUBAC
FZ0
G-S
G.N
GODZA
H.X
HF~
HGLYW
HVGLF
HZI
HZ~
IH2
IHE
IPNFZ
IX1
J0M
J5H
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OBS
OHT
OIG
OK1
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
Q~Q
R.K
RIWAO
RJQFR
ROL
RX1
SAMSI
SUPJJ
SV3
TEORI
TUS
UB1
V8K
W8V
W99
WBKPD
WH7
WHWMO
WIH
WIJ
WIK
WIN
WOHZO
WOW
WQJ
WRC
WUP
WVDHM
WXI
WXSBR
X7M
XG1
Y6R
YFH
YOC
YUY
ZGI
ZXP
ZZTAW
~IA
~KM
~WT
AAYXX
AEYWJ
AGHNM
AGQPQ
AGYGG
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QP
7QR
7T5
7TK
7U9
8FD
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
FR3
H94
K9.
M7N
NAPCQ
P64
7X8
ID FETCH-LOGICAL-c3883-569c110c1bd2e2f02d9ce8b072321308552823ed7fa8d086761c1c7dfd5694913
IEDL.DBID DR2
ISSN 0300-9475
1365-3083
IngestDate Fri Jul 11 03:00:18 EDT 2025
Fri Jul 25 09:31:28 EDT 2025
Thu Apr 03 07:03:13 EDT 2025
Thu Apr 24 23:03:17 EDT 2025
Tue Jul 01 03:57:00 EDT 2025
Wed Jan 22 16:35:35 EST 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords diseases
experimental animals
processes
cancer
subject
vaccination
Language English
License 2019 The Scandinavian Foundation for Immunology.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3883-569c110c1bd2e2f02d9ce8b072321308552823ed7fa8d086761c1c7dfd5694913
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ORCID 0000-0002-3227-2938
OpenAccessLink https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/sji.12833
PMID 31544248
PQID 2339414955
PQPubID 37516
PageCount 10
ParticipantIDs proquest_miscellaneous_2296120001
proquest_journals_2339414955
pubmed_primary_31544248
crossref_citationtrail_10_1111_sji_12833
crossref_primary_10_1111_sji_12833
wiley_primary_10_1111_sji_12833_SJI12833
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate February 2020
2020-02-00
2020-Feb
20200201
PublicationDateYYYYMMDD 2020-02-01
PublicationDate_xml – month: 02
  year: 2020
  text: February 2020
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: Oxford
PublicationTitle Scandinavian journal of immunology
PublicationTitleAlternate Scand J Immunol
PublicationYear 2020
Publisher Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Subscription Services, Inc
References 1995; 73
2017; 8
2014; 70
1990; 12
2012; 2012
2000; 49
2011; 436
2002; 51
2015; 72
2002; 12
2013; 368
2018; 167
2015; 33
2013; 20
2015; 220
1983; 5
2015; 32
1999; 163
2008; 5
1992; 14
2003; 19
1988; 74
2009; 230
2011; 151
2013; 5
2008; 2008
2013; 19
1993; 37
2010; 1
2018; 535
1997; 15
2019; 26
1991; 92
2013; 156
1985; 135
1985
1997; 17
2017; 165
2012; 24
2018; 180
1992; 45
1996; 64
2016; 46
2014; 10
2007; 18
1990; 32
1991; 39
2015; 5
2010; 2010
1994; 511
2015; 3
2012
2017; 28
2010; 39
2002; 5
2002; 35
1985; 7
2008; 10
2016; 93
1999; 221
2014; 110
2006; 116
2015; 9
2017; 134
1998; 20
2012; 33
2016; 59
2009; 26
2016; 11
1993; 15
2009; 77
1987; 23
1989; 11
2012; 354
2004; 93
2015; 64
2002; 169
2018; 555
1983; 40
2005; 98
2017
2005; 10
2017; 18
1988; 63
2018; 98
2013; 172
1996; 156
2012; 88
2003; 221
2008; 80
1985; 79
2014; 102
e_1_2_11_70_1
e_1_2_11_93_1
e_1_2_11_32_1
e_1_2_11_55_1
e_1_2_11_78_1
e_1_2_11_36_1
e_1_2_11_51_1
e_1_2_11_74_1
e_1_2_11_97_1
e_1_2_11_13_1
e_1_2_11_4_1
e_1_2_11_48_1
Matsuoka H (e_1_2_11_24_1) 1997; 17
Thornton BP (e_1_2_11_7_1) 1996; 156
e_1_2_11_81_1
e_1_2_11_20_1
e_1_2_11_66_1
e_1_2_11_47_1
e_1_2_11_89_1
e_1_2_11_62_1
e_1_2_11_43_1
e_1_2_11_85_1
e_1_2_11_17_1
e_1_2_11_59_1
Garçon N (e_1_2_11_37_1) 2012
Centers for Disease Control and Prevention (CDC) (e_1_2_11_35_1) 2000; 49
e_1_2_11_50_1
e_1_2_11_92_1
e_1_2_11_31_1
e_1_2_11_77_1
e_1_2_11_58_1
e_1_2_11_73_1
e_1_2_11_12_1
e_1_2_11_54_1
e_1_2_11_96_1
Vetvicka V (e_1_2_11_63_1) 2015; 3
e_1_2_11_28_1
Yan J (e_1_2_11_8_1) 1999; 163
e_1_2_11_61_1
e_1_2_11_80_1
e_1_2_11_46_1
e_1_2_11_69_1
e_1_2_11_88_1
e_1_2_11_9_1
e_1_2_11_23_1
e_1_2_11_42_1
e_1_2_11_65_1
e_1_2_11_84_1
Vetvicka V (e_1_2_11_21_1) 2002; 5
e_1_2_11_16_1
He Y (e_1_2_11_40_1) 2010; 2010
e_1_2_11_39_1
e_1_2_11_72_1
e_1_2_11_91_1
Soto E (e_1_2_11_6_1) 2008; 2008
e_1_2_11_30_1
e_1_2_11_57_1
e_1_2_11_34_1
e_1_2_11_53_1
e_1_2_11_76_1
e_1_2_11_95_1
e_1_2_11_11_1
e_1_2_11_27_1
e_1_2_11_2_1
e_1_2_11_83_1
e_1_2_11_60_1
e_1_2_11_45_1
e_1_2_11_68_1
e_1_2_11_41_1
e_1_2_11_87_1
e_1_2_11_22_1
e_1_2_11_64_1
e_1_2_11_15_1
e_1_2_11_38_1
e_1_2_11_19_1
Hanaue H (e_1_2_11_29_1) 1989; 11
e_1_2_11_94_1
e_1_2_11_71_1
e_1_2_11_90_1
Takeshita K (e_1_2_11_25_1) 1991; 92
e_1_2_11_10_1
e_1_2_11_56_1
e_1_2_11_79_1
e_1_2_11_14_1
e_1_2_11_52_1
e_1_2_11_98_1
e_1_2_11_33_1
e_1_2_11_75_1
Torrence PF (e_1_2_11_5_1) 1985
e_1_2_11_26_1
e_1_2_11_3_1
e_1_2_11_49_1
e_1_2_11_82_1
e_1_2_11_44_1
e_1_2_11_67_1
e_1_2_11_86_1
e_1_2_11_18_1
References_xml – volume: 26
  start-page: 32
  year: 2019
  end-page: 40
  article-title: Complex consisting of antisense DNA and beta‐glucan promotes internalization into cell through Dectin‐1 and hybridizes with target mRNA in cytosol
  publication-title: Cancer Gene Ther
– volume: 64
  start-page: 1237
  year: 2015
  end-page: 1243
  article-title: Whole glucan particles as a vaccine against systemic coccidioidomycosis
  publication-title: J Med Microbiol
– volume: 24
  start-page: 343
  year: 2012
  end-page: 353
  article-title: Vaccines against mucosal infections
  publication-title: Curr Opin Immunol
– volume: 163
  start-page: 3045
  year: 1999
  end-page: 3052
  article-title: Beta‐glucan, a "specific" biologic response modifier that uses antibodies to target tumors for cytotoxic recognition by leukocyte complement receptor type 3 (CD11b/CD18)
  publication-title: J Immunol
– volume: 32
  start-page: 321
  year: 1990
  end-page: 331
  article-title: Dynamics of blood components and peritoneal fluid during treatment of murine E. coli sepsis with beta‐1,3‐D‐polyglucose derivatives. I. Cells
  publication-title: Scand J Immunol
– volume: 555
  start-page: 469
  year: 2018
  end-page: 474
  article-title: DNA methylation‐based classification of central nervous system tumours
  publication-title: Nature
– volume: 14
  start-page: 1363
  year: 1992
  end-page: 1373
  article-title: Stimulation of human monocyte beta‐glucan receptors by glucan particles induces production of TNF‐alpha and IL‐1 beta
  publication-title: Int J Immunopharmacol
– volume: 32
  start-page: 755
  year: 2015
  end-page: 768
  article-title: Development of chitosan‐pullulan composite nanoparticles for nasal delivery of vaccines: optimisation and cellular studies
  publication-title: J Microencapsul
– volume: 12
  start-page: 185
  year: 2002
  end-page: 197
  article-title: Liposome (Lipodine)‐mediated DNA vaccination by the oral route
  publication-title: J Liposome Res
– volume: 18
  start-page: 537
  year: 2007
  end-page: 545
  article-title: Virus‐like particles‐universal molecular toolboxes
  publication-title: Curr Opin Biotechnol
– volume: 167
  start-page: 32
  year: 2018
  end-page: 43
  article-title: Aluminum hydroxide colloid vaccine encapsulated in yeast shells with enhanced humoral and cellular immune responses
  publication-title: Biomaterials
– volume: 116
  start-page: 1
  year: 2006
  end-page: 27
  article-title: Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach
  publication-title: J Control Release
– volume: 156
  start-page: 1235
  year: 1996
  end-page: 1246
  article-title: Analysis of the sugar specificity and molecular location of the beta‐glucan‐binding lectin site of complement receptor type 3 (CD11b/CD18)
  publication-title: J Immunol
– volume: 5
  start-page: 580
  year: 2013
  end-page: 588
  article-title: The effects of beta ‐ glucan on fish immunity
  publication-title: N Am J Med Sci
– volume: 72
  start-page: 588
  year: 2015
  end-page: 598
  article-title: Biological activities of derivatized D‐glucans: a review
  publication-title: Int J Biol Macromol
– start-page: 58
  year: 2012
  end-page: 70
– volume: 26
  start-page: 29
  year: 2009
  end-page: 84
  article-title: Recent developments of biodegradable and biocompatible materials based micro/nanoparticles for delivering macromolecular therapeutics
  publication-title: Crit Rev Ther Drug Carrier Syst
– volume: 5
  start-page: 10687
  year: 2015
  article-title: Efficient delivery of antigen to DCs using yeast‐derived microparticles
  publication-title: Sci Rep
– volume: 80
  start-page: 1053
  year: 2008
  end-page: 1061
  article-title: Conjugation of protein antigen to microparticulate beta‐glucan from Saccharomyces cerevisiae: a new adjuvant for intradermal and oral immunizations
  publication-title: Appl Microbiol Biotechnol
– volume: 37
  start-page: 19
  year: 1993
  end-page: 25
  article-title: Fungal beta‐glucans modulate macrophage release of tumor necrosis factor‐alpha in response to bacterial lipopolysaccharide
  publication-title: Immunol Lett
– volume: 77
  start-page: 1774
  year: 2009
  end-page: 1781
  article-title: Distinct patterns of dendritic cell cytokine release stimulated by fungal beta‐glucans and toll‐like receptor agonists
  publication-title: Infect Immun
– volume: 134
  start-page: 51
  year: 2017
  end-page: 63
  article-title: A novel antigen delivery system induces strong humoral and CTL immune responses
  publication-title: Biomaterials
– volume: 70
  start-page: 193
  year: 2014
  end-page: 198
  article-title: Sulfated glucan can improve the immune efficacy of Newcastle disease vaccine in chicken
  publication-title: Int J Biol Macromol
– volume: 354
  start-page: 75
  year: 2012
  end-page: 99
  article-title: Recent advances in microparticle and nanoparticle delivery vehicles for mucosal vaccination
  publication-title: Curr Top Microbiol Immunol
– volume: 93
  start-page: 203
  year: 2016
  end-page: 207
  article-title: Improvement of immune responses to influenza vaccine (H5N1) by sulfated yeast beta‐glucan
  publication-title: Int J Biol Macromol
– volume: 110
  start-page: 446
  year: 2014
  end-page: 455
  article-title: Effect and mechanisms of curdlan sulfate on inhibiting HBV infection and acting as an HB vaccine adjuvant
  publication-title: Carbohydr Polym
– volume: 92
  start-page: 5
  year: 1991
  end-page: 11
  article-title: [Diversity of complement activation by lentinan, an antitumor polysaccharide, in gastric cancer patients]. Nihon Geka Gakkai
  publication-title: Zasshi
– volume: 14
  start-page: 173
  year: 1992
  end-page: 183
  article-title: Comparative effects of particulate and soluble glucan on macrophages of C3H/HeN and C3H/HeJ mice
  publication-title: Int J Immunopharmacol
– volume: 221
  start-page: 1
  year: 2003
  end-page: 5
  article-title: Immunopotentiation of intraepithelial lymphocytes in the intestine by oral administrations of beta‐glucan
  publication-title: Cell Immunol
– volume: 230
  start-page: 38
  year: 2009
  end-page: 50
  article-title: Beta‐glucan recognition by the innate immune system
  publication-title: Immunol Rev
– volume: 49
  start-page: 1094
  year: 2000
  end-page: 1103
  article-title: Outbreak of poliomyelitis–Dominican Republic and Haiti, 2000
  publication-title: MMWR Morb Mortal Wkly Rep
– volume: 156
  start-page: 167
  year: 2013
  end-page: 175
  article-title: Adjuvant and immunostimulatory effects of LPS and β‐glucan on immune response in Japanese flounder, Paralichthys olivaceus
  publication-title: Vet Immunol Immunopathol
– volume: 102
  start-page: 852
  year: 2014
  end-page: 861
  article-title: Preparation and in vitro immunomodulatory effect of curdlan sulfate
  publication-title: Carbohydr Polym
– volume: 2010
  start-page: 218590
  year: 2010
  article-title: Emerging vaccine informatics
  publication-title: J Biomed Biotechnol
– volume: 28
  start-page: 565
  year: 2017
  end-page: 573
  article-title: Adjuvant activity enhanced by cross‐Linked CpG‐oligonucleotides in beta‐glucan nanogel and its antitumor effect
  publication-title: Bioconjug Chem
– volume: 2008
  start-page: 332
  issue: 2
  year: 2008
  end-page: 335
  article-title: Glucan particles as an efficient siRNA delivery vehicle. NSTI‐Nanotech 2008
  publication-title: Techn Proc
– volume: 15
  start-page: 814
  year: 1997
  end-page: 817
  article-title: Poly(DL‐lactide‐co‐glycolide)‐encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration
  publication-title: Vaccine
– volume: 180
  start-page: 365
  year: 2018
  end-page: 375
  article-title: 1, 3beta‐Glucan anchored, paclitaxel loaded chitosan nanocarrier endows enhanced hemocompatibility with efficient anti‐glioblastoma stem cells therapy
  publication-title: Carbohydr Polym
– volume: 436
  start-page: 351
  year: 2011
  end-page: 362
  article-title: Glucan particles for selective delivery of siRNA to phagocytic cells in mice
  publication-title: Biochem J
– volume: 39
  start-page: 303
  year: 2010
  end-page: 355
  article-title: Function of mucosa‐associated lymphoid tissue in antibody formation
  publication-title: Immunol Invest
– volume: 17
  start-page: 2751
  year: 1997
  end-page: 2755
  article-title: Lentinan potentiates immunity and prolongs the survival time of some patients
  publication-title: Anticancer Res
– volume: 40
  start-page: 1038
  year: 1983
  end-page: 1043
  article-title: Immunogenicity of soluble and particulate antigens from Leishmania donovani: effect of glucan as an adjuvant
  publication-title: Infect Immun
– volume: 33
  start-page: 2399
  year: 2015
  end-page: 2405
  article-title: Advances and challenges in mucosal adjuvant technology
  publication-title: Vaccine
– volume: 23
  start-page: 363
  year: 1987
  end-page: 365
  article-title: Effect of glucan on Leishmania major infection in BALB/c mice
  publication-title: J Med Microbiol
– volume: 19
  start-page: 311
  year: 2003
  end-page: 315
  article-title: Fungal beta‐glucans and mammalian immunity
  publication-title: Immunity
– volume: 45
  start-page: 1778
  year: 1992
  end-page: 1784
  article-title: Enhancement by ubenimex (bestatin) of host resistance to Candida albicans infection
  publication-title: J Antibiot
– volume: 98
  start-page: 2617
  year: 2018
  end-page: 2623
  article-title: Preparation and characterisation of a novel hydrogel based on Auricularia polytricha beta‐glucan and its bio‐release property for vitamin B12 delivery
  publication-title: J Sci Food Agric
– volume: 11
  start-page: 614
  year: 1989
  end-page: 622
  article-title: Effects of oral lentinan on T‐cell subsets in peripheral venous blood
  publication-title: Clin Ther
– volume: 98
  start-page: 115
  year: 2005
  end-page: 122
  article-title: IFN‐gamma primes macrophages for enhanced TNF‐alpha expression in response to stimulatory and non‐stimulatory amounts of microparticulate beta‐glucan
  publication-title: Immunol Lett
– volume: 3
  start-page: 22
  year: 2015
  article-title: Glucan supplementation enhances the immune response against an influenza challenge in mice
  publication-title: Ann Transl Med
– volume: 7
  start-page: 923
  year: 1985
  end-page: 932
  article-title: Stimulated hemopoiesis and enhanced survival following glucan treatment in sublethally and lethally irradiated mice
  publication-title: Int J Immunopharmacol
– volume: 2012
  start-page: 831486
  year: 2012
  article-title: Vaxjo: a web‐based vaccine adjuvant database and its application for analysis of vaccine adjuvants and their uses in vaccine development
  publication-title: J Biomed Biotechnol
– volume: 93
  start-page: 71
  year: 2004
  end-page: 78
  article-title: Microparticulate beta‐glucan upregulates the expression of B7.1, B7.2, B7–H1, but not B7‐DC on cultured murine peritoneal macrophages
  publication-title: Immunol Lett
– volume: 165
  start-page: 103
  year: 2017
  end-page: 114
  article-title: Potential of glucans as vaccine adjuvants: a review of the alpha‐glucans case
  publication-title: Carbohydr Polym
– volume: 64
  start-page: 2201
  year: 1996
  end-page: 2205
  article-title: Passive transfer of poly‐(1–6)‐beta‐glucotriosyl‐(1–3)‐beta‐glucopyranose glucan protection against lethal infection in an animal model of intra‐abdominal sepsis
  publication-title: Infect Immun
– year: 1985
– start-page: 143
  year: 2017
  end-page: 157
– volume: 172
  start-page: 671
  year: 2013
  end-page: 678
  article-title: beta‐Glucan microparticles are good candidates for mucosal antigen delivery in oral vaccination
  publication-title: J Control Release
– volume: 28
  start-page: 2246
  year: 2017
  end-page: 2253
  article-title: Complex consisting of beta‐glucan and antigenic peptides with cleavage site for glutathione and aminopeptidases induces potent cytotoxic T lymphocytes
  publication-title: Bioconjug Chem
– volume: 368
  start-page: 551
  year: 2013
  end-page: 560
  article-title: Designing tomorrow's vaccines
  publication-title: N Engl J Med
– volume: 46
  start-page: 1142
  year: 2016
  end-page: 1151
  article-title: Species‐dependent role of type I IFNs and IL‐12 in the CTL response induced by humanized CpG complexed with beta‐glucan
  publication-title: Eur J Immunol
– volume: 151
  start-page: 155
  year: 2011
  end-page: 161
  article-title: Dectin‐1 targeting delivery of TNF‐alpha antisense ODNs complexed with beta‐1,3‐glucan protects mice from LPS‐induced hepatitis
  publication-title: J Control Release
– volume: 535
  start-page: 261
  year: 2018
  end-page: 271
  article-title: Oral hepatitis B vaccine: chitosan or glucan based delivery systems for efficient HBsAg immunization following subcutaneous priming
  publication-title: Int J Pharm
– volume: 20
  start-page: 1585
  year: 2013
  end-page: 1591
  article-title: Characterization and optimization of the glucan particle‐based vaccine platform
  publication-title: Clin Vaccine Immunol
– volume: 15
  start-page: 227
  year: 1993
  end-page: 242
  article-title: The effect of two glucan carboxymethyl derivatives with various substitution degrees on cyclophosphamide immunosuppression in mice
  publication-title: Immunopharmacol Immunotoxicol
– volume: 135
  start-page: 3388
  year: 1985
  end-page: 3393
  article-title: Properties of glycans that activate the human alternative complement pathway and interact with the human monocyte beta‐glucan receptor
  publication-title: J Immunol
– volume: 8
  year: 2017
  article-title: . Vaccination with recombinant cryptococcus proteins in glucan particles protects mice against cryptococcosis in a manner dependent upon mouse strain and Cryptococcal species
  publication-title: MBio
– volume: 51
  start-page: 557
  year: 2002
  end-page: 564
  article-title: Orally administered beta‐glucans enhance anti‐tumor effects of monoclonal antibodies
  publication-title: Cancer Immunol Immunother
– volume: 10
  start-page: 1145
  year: 2005
  end-page: 1157
  article-title: Keynote review: intestinal Peyer's patch M cells and oral vaccine targeting
  publication-title: Drug Discov Today
– volume: 39
  start-page: 1606
  year: 1991
  end-page: 1608
  article-title: Inhibition of experimental pulmonary metastasis of Lewis lung carcinoma by orally administered beta‐glucan in mice
  publication-title: Chem Pharm Bull
– volume: 18
  start-page: 1172
  year: 2017
  end-page: 1179
  article-title: Oral gavage delivery of PR8 antigen with beta‐glucan‐conjugated GRGDS carrier to enhance M‐cell targeting ability and induce immunity
  publication-title: Biomacromol
– volume: 11
  start-page: 403
  year: 1989
  end-page: 410
  article-title: Immunization against Trypanosoma cruzi: adjuvant effect of glucan
  publication-title: Int J Immunopharmacol
– volume: 9
  start-page: 88
  year: 2015
  end-page: 93
  article-title: Polysaccharides: candidates of promising vaccine adjuvants
  publication-title: Drug Discov Ther
– volume: 19
  start-page: 1597
  year: 2013
  end-page: 1608
  article-title: Key roles of adjuvants in modern vaccines
  publication-title: Nat Med
– volume: 10
  start-page: 1309
  year: 2014
  end-page: 1318
  article-title: Recent advances in oral vaccine development: yeast‐derived beta‐glucan particles
  publication-title: Hum Vaccin Immunother
– volume: 11
  start-page: 2463
  year: 2016
  end-page: 2469
  article-title: Duality of beta‐glucan microparticles: antigen carrier and immunostimulants
  publication-title: Int J Nanomedicine
– volume: 1
  year: 2010
  article-title: Robust stimulation of humoral and cellular immune responses following vaccination with antigen‐loaded beta‐glucan particles
  publication-title: MBio
– volume: 5
  start-page: 47
  year: 2008
  end-page: 57
  article-title: Beta‐glucans, history, and the present: immunomodulatory aspects and mechanisms of action
  publication-title: J Immunotoxicol
– volume: 59
  start-page: 36
  year: 2016
  end-page: 45
  article-title: beta‐1,3/1,6‐Glucan‐supplemented diets antagonize immune inhibitory effects of hypoxia and enhance the immune response to a model vaccine
  publication-title: Fish Shellfish Immunol
– volume: 33
  start-page: 5302
  year: 2015
  end-page: 5307
  article-title: Molecular signatures of vaccine adjuvants
  publication-title: Vaccine
– volume: 5
  start-page: 1
  year: 2002
  end-page: 5
  article-title: Pilot study: Orally‐administered yeast β1,3‐glucan prophylactically protects against anthrax infectin and cancer in mice
  publication-title: JANA
– volume: 35
  start-page: 267
  year: 2002
  end-page: 271
  article-title: Preparation of microparticulate beta‐glucan from Saccharomyces cerevisiae for use in immune potentiation
  publication-title: Lett Appl Microbiol
– volume: 221
  start-page: 281
  year: 1999
  end-page: 293
  article-title: Mushrooms, tumors, and immunity
  publication-title: Proc Soc Exp Biol Med
– volume: 33
  start-page: 111
  year: 2012
  end-page: 120
  article-title: Immunomodulatory effects of dietary beta‐1,3‐glucan from Euglena gracilis in rainbow trout (Oncorhynchus mykiss) immersion vaccinated against Yersinia ruckeri
  publication-title: Fish Shellfish Immunol
– volume: 88
  start-page: 966
  year: 2012
  end-page: 972
  article-title: Cationization of Ganoderma lucidum polysaccharides in concentrated alkaline solutions as gene carriers
  publication-title: Carbohyd Polym
– volume: 511
  start-page: 192
  year: 1994
  end-page: 195
  article-title: Clinical evaluation of sizofilan as assistant immunotherapy in treatment of head and neck cancer
  publication-title: Acta Otolaryngol Suppl
– volume: 220
  start-page: 149
  year: 2015
  end-page: 159
  article-title: beta‐glucan microparticles targeted to epithelial APN as oral antigen delivery system
  publication-title: J Control Release
– volume: 20
  start-page: 595
  year: 1998
  end-page: 614
  article-title: Enhanced clearance of a multiple antibiotic resistant Staphylococcus aureus in rats treated with PGG‐glucan is associated with increased leukocyte counts and increased neutrophil oxidative burst activity
  publication-title: Int J Immunopharmacol
– volume: 74
  start-page: 563
  year: 1988
  end-page: 568
  article-title: The effect of lentinan on the resistance of mice to Mesocestoides corti
  publication-title: Parasitol Res
– volume: 79
  start-page: 211
  year: 1985
  end-page: 213
  article-title: Glucan‐induced immunity in mice against Plasmodium berghei
  publication-title: Ann Trop Med Parasitol
– volume: 5
  start-page: 303
  year: 1983
  end-page: 313
  article-title: Dose‐dependent responses of murine pluripotent stem cells and myeloid and erythroid progenitor cells following administration of the immunomodulating agent glucan
  publication-title: Immunopharmacology
– volume: 73
  start-page: 3341
  year: 1995
  end-page: 3350
  article-title: Influence of dietary beta‐glucan on growth performance, nonspecific immunity, and resistance to Streptococcus suis infection in weanling pigs
  publication-title: J Anim Sci
– volume: 10
  start-page: 2058
  year: 2008
  end-page: 2066
  article-title: Dectin‐1 synergizes with TLR2 and TLR4 for cytokine production in human primary monocytes and macrophages
  publication-title: Cell Microbiol
– volume: 12
  start-page: 675
  year: 1990
  end-page: 684
  article-title: Effect of orally administered beta‐glucan on macrophage function in mice
  publication-title: Int J Immunopharmacol
– volume: 63
  start-page: 398
  year: 1988
  end-page: 409
  article-title: [Enhancement of resistance of mice Toxoplasma gondii by 2 polysaccharides beta 1–3, beta 1–6 (PSAT and Scleroglucan)]
  publication-title: Ann Parasitol Hum Comp
– volume: 33
  start-page: 1279
  year: 2015
  end-page: 1293
  article-title: Nanoengineering of vaccines using natural polysaccharides
  publication-title: Biotechnol Adv
– volume: 169
  start-page: 3876
  year: 2002
  end-page: 3882
  article-title: The beta‐glucan receptor, dectin‐1, is predominantly expressed on the surface of cells of the monocyte/macrophage and neutrophil lineages
  publication-title: J Immunol
– ident: e_1_2_11_88_1
  doi: 10.1615/CritRevTherDrugCarrierSyst.v26.i1.20
– volume: 49
  start-page: 1094
  year: 2000
  ident: e_1_2_11_35_1
  article-title: Outbreak of poliomyelitis–Dominican Republic and Haiti, 2000
  publication-title: MMWR Morb Mortal Wkly Rep
– ident: e_1_2_11_55_1
  doi: 10.1016/j.vetimm.2013.10.004
– volume: 17
  start-page: 2751
  year: 1997
  ident: e_1_2_11_24_1
  article-title: Lentinan potentiates immunity and prolongs the survival time of some patients
  publication-title: Anticancer Res
– ident: e_1_2_11_11_1
  doi: 10.1099/00222615-23-4-363
– ident: e_1_2_11_26_1
  doi: 10.1016/0162-3109(83)90046-2
– ident: e_1_2_11_53_1
  doi: 10.1016/0192-0561(92)90007-8
– start-page: 58
  volume-title: Vaccines
  year: 2012
  ident: e_1_2_11_37_1
– ident: e_1_2_11_48_1
  doi: 10.1016/j.imlet.2004.02.006
– ident: e_1_2_11_57_1
  doi: 10.1111/j.1462-5822.2008.01188.x
– ident: e_1_2_11_73_1
  doi: 10.1002/jsfa.8754
– ident: e_1_2_11_15_1
  doi: 10.2527/1995.73113341x
– ident: e_1_2_11_83_1
  doi: 10.1038/s41417-018-0033-2
– ident: e_1_2_11_61_1
  doi: 10.1016/j.carbpol.2014.04.025
– ident: e_1_2_11_54_1
  doi: 10.4103/1947-2714.120792
– ident: e_1_2_11_45_1
  doi: 10.5582/ddt.2015.01025
– ident: e_1_2_11_72_1
  doi: 10.1016/j.carbpol.2017.10.030
– ident: e_1_2_11_90_1
  doi: 10.3109/02652048.2015.1073392
– ident: e_1_2_11_50_1
  doi: 10.1016/j.imlet.2004.10.020
– ident: e_1_2_11_92_1
  doi: 10.1016/j.jconrel.2015.10.025
– ident: e_1_2_11_85_1
  doi: 10.1021/acs.biomac.6b01855
– ident: e_1_2_11_12_1
  doi: 10.1128/IAI.40.3.1038-1043.1983
– volume: 2008
  start-page: 332
  issue: 2
  year: 2008
  ident: e_1_2_11_6_1
  article-title: Glucan particles as an efficient siRNA delivery vehicle. NSTI‐Nanotech 2008
  publication-title: Techn Proc
– ident: e_1_2_11_31_1
  doi: 10.1016/0192-0561(90)90105-V
– ident: e_1_2_11_67_1
  doi: 10.1128/mBio.00164-10
– volume: 11
  start-page: 614
  year: 1989
  ident: e_1_2_11_29_1
  article-title: Effects of oral lentinan on T‐cell subsets in peripheral venous blood
  publication-title: Clin Ther
– ident: e_1_2_11_30_1
  doi: 10.1248/cpb.39.1606
– ident: e_1_2_11_16_1
  doi: 10.1080/00034983.1985.11811908
– ident: e_1_2_11_62_1
  doi: 10.1016/j.ijbiomac.2016.06.057
– ident: e_1_2_11_43_1
  doi: 10.1016/j.ijbiomac.2014.09.008
– ident: e_1_2_11_13_1
  doi: 10.7164/antibiotics.45.1778
– ident: e_1_2_11_77_1
  doi: 10.1016/j.jconrel.2013.09.007
– ident: e_1_2_11_87_1
  doi: 10.1081/LPR-120004792
– ident: e_1_2_11_95_1
  doi: 10.1016/j.coi.2012.03.014
– ident: e_1_2_11_39_1
  doi: 10.1038/nm.3409
– ident: e_1_2_11_65_1
  doi: 10.1128/mBio.01872-17
– ident: e_1_2_11_86_1
  doi: 10.1016/j.copbio.2007.10.013
– volume: 5
  start-page: 1
  year: 2002
  ident: e_1_2_11_21_1
  article-title: Pilot study: Orally‐administered yeast β1,3‐glucan prophylactically protects against anthrax infectin and cancer in mice
  publication-title: JANA
– ident: e_1_2_11_60_1
  doi: 10.1016/j.fsi.2016.10.020
– ident: e_1_2_11_82_1
  doi: 10.1002/eji.201546059
– ident: e_1_2_11_70_1
  doi: 10.1016/j.biomaterials.2018.03.014
– ident: e_1_2_11_27_1
  doi: 10.1016/0192-0561(85)90056-6
– ident: e_1_2_11_22_1
  doi: 10.1128/IAI.64.6.2201-2205.1996
– ident: e_1_2_11_23_1
  doi: 10.3109/00016489409128330
– ident: e_1_2_11_44_1
  doi: 10.1016/j.carbpol.2017.02.030
– ident: e_1_2_11_89_1
  doi: 10.4161/hv.28166
– volume: 156
  start-page: 1235
  year: 1996
  ident: e_1_2_11_7_1
  article-title: Analysis of the sugar specificity and molecular location of the beta‐glucan‐binding lectin site of complement receptor type 3 (CD11b/CD18)
  publication-title: J Immunol
  doi: 10.4049/jimmunol.156.3.1235
– ident: e_1_2_11_52_1
  doi: 10.1016/0165-2478(93)90127-N
– ident: e_1_2_11_56_1
  doi: 10.1016/j.ijbiomac.2014.05.048
– ident: e_1_2_11_34_1
  doi: 10.1056/NEJMra1204186
– ident: e_1_2_11_80_1
  doi: 10.1016/j.carbpol.2012.01.054
– volume-title: Biological Response Modifiers: New Approaches to Disease Intervention
  year: 1985
  ident: e_1_2_11_5_1
– ident: e_1_2_11_51_1
  doi: 10.1007/s00253-008-1618-8
– ident: e_1_2_11_74_1
  doi: 10.1016/j.biotechadv.2015.05.010
– ident: e_1_2_11_91_1
  doi: 10.2147/IJN.S101881
– ident: e_1_2_11_20_1
  doi: 10.1016/0192-0561(89)90087-8
– ident: e_1_2_11_46_1
  doi: 10.1111/j.1600-065X.2009.00793.x
– ident: e_1_2_11_84_1
  doi: 10.1021/acs.bioconjchem.7b00159
– ident: e_1_2_11_18_1
  doi: 10.1111/j.1365-3083.1990.tb02926.x
– ident: e_1_2_11_32_1
  doi: 10.1007/s00262-002-0321-3
– volume: 3
  start-page: 22
  year: 2015
  ident: e_1_2_11_63_1
  article-title: Glucan supplementation enhances the immune response against an influenza challenge in mice
  publication-title: Ann Transl Med
– ident: e_1_2_11_94_1
  doi: 10.1016/S0264-410X(96)00266-6
– ident: e_1_2_11_2_1
  doi: 10.1046/j.1525-1373.1999.d01-86.x
– ident: e_1_2_11_93_1
  doi: 10.1016/j.jconrel.2006.08.013
– ident: e_1_2_11_33_1
  doi: 10.1016/S0008-8749(03)00061-3
– ident: e_1_2_11_98_1
  doi: 10.1016/S1359-6446(05)03536-1
– ident: e_1_2_11_69_1
  doi: 10.1021/acs.bioconjchem.6b00675
– ident: e_1_2_11_14_1
  doi: 10.1051/parasite/1988636398
– ident: e_1_2_11_75_1
  doi: 10.1016/j.biomaterials.2017.04.035
– ident: e_1_2_11_17_1
  doi: 10.1016/S0192-0561(98)00007-1
– ident: e_1_2_11_64_1
  doi: 10.1099/jmm.0.000138
– ident: e_1_2_11_78_1
  doi: 10.1128/CVI.00463-13
– ident: e_1_2_11_28_1
  doi: 10.3109/08923979309025996
– ident: e_1_2_11_81_1
  doi: 10.1016/j.jconrel.2011.01.026
– ident: e_1_2_11_49_1
  doi: 10.1046/j.1472-765X.2002.01201.x
– ident: e_1_2_11_10_1
  doi: 10.4049/jimmunol.135.5.3388
– ident: e_1_2_11_19_1
  doi: 10.1007/BF00531635
– volume: 92
  start-page: 5
  year: 1991
  ident: e_1_2_11_25_1
  article-title: [Diversity of complement activation by lentinan, an antitumor polysaccharide, in gastric cancer patients]. Nihon Geka Gakkai
  publication-title: Zasshi
– ident: e_1_2_11_59_1
  doi: 10.1016/j.fsi.2012.04.009
– ident: e_1_2_11_71_1
  doi: 10.1038/nature26000
– volume: 2010
  start-page: 218590
  year: 2010
  ident: e_1_2_11_40_1
  article-title: Emerging vaccine informatics
  publication-title: J Biomed Biotechnol
– ident: e_1_2_11_76_1
  doi: 10.1016/j.ijpharm.2017.11.009
– ident: e_1_2_11_3_1
  doi: 10.1016/S1074-7613(03)00233-4
– ident: e_1_2_11_4_1
  doi: 10.1080/15476910802019045
– ident: e_1_2_11_41_1
  doi: 10.1155/2012/831486
– ident: e_1_2_11_47_1
  doi: 10.1016/0192-0561(92)90028-J
– ident: e_1_2_11_79_1
  doi: 10.1038/srep10687
– ident: e_1_2_11_66_1
  doi: 10.1007/978-1-4939-7104-6_11
– ident: e_1_2_11_36_1
  doi: 10.1007/82_2011_140
– ident: e_1_2_11_96_1
  doi: 10.1042/BJ20110352
– volume: 163
  start-page: 3045
  year: 1999
  ident: e_1_2_11_8_1
  article-title: Beta‐glucan, a "specific" biologic response modifier that uses antibodies to target tumors for cytotoxic recognition by leukocyte complement receptor type 3 (CD11b/CD18)
  publication-title: J Immunol
  doi: 10.4049/jimmunol.163.6.3045
– ident: e_1_2_11_9_1
  doi: 10.4049/jimmunol.169.7.3876
– ident: e_1_2_11_42_1
  doi: 10.1016/j.vaccine.2015.03.096
– ident: e_1_2_11_68_1
  doi: 10.1128/IAI.00086-09
– ident: e_1_2_11_97_1
  doi: 10.3109/08820131003680369
– ident: e_1_2_11_58_1
  doi: 10.1016/j.carbpol.2013.10.078
– ident: e_1_2_11_38_1
  doi: 10.1016/j.vaccine.2015.04.099
SSID ssj0013273
Score 2.4745104
SecondaryResourceType review_article
Snippet Vaccination constitutes one of the major breakthroughs in human medicine. At the same time, development of more immunogenic vaccine alternatives to using...
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage e12833
SubjectTerms Adjuvants
Adjuvants, Immunologic
Aluminum
Animals
Antigen Presentation
Antigen-presenting cells
Antigens
beta-Glucans - immunology
beta-Glucans - therapeutic use
cancer
diseases
Drug Delivery Systems - methods
experimental animals
Glucans
Humans
Hydrogels
Hydrogels - therapeutic use
Immunization
Immunogenicity
Oligodeoxyribonucleotides
Oligonucleotides
processes
subject
Vaccination
Vaccine development
Vaccines
Vaccines - immunology
β-Glucan
Title β‐glucan as a new tool in vaccine development
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fsji.12833
https://www.ncbi.nlm.nih.gov/pubmed/31544248
https://www.proquest.com/docview/2339414955
https://www.proquest.com/docview/2296120001
Volume 91
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JSgQxEC1EULy4jNu4EcWDlx56kl7SeBJxUEEPLuBBaNJJGlzoEWdG0JOf4Lf4IX6EX2JVb-4g3hq6QrpTqeS9ruoXgHVPKDdQ2nUIvDteaBJHKus6XkQ5mUSmgSKieHAY7J56-2f-2RBsVv_CFPoQ9Qc3iox8vaYAV0nvQ5D3Li9auLgKUvqkWi0CREf8QwahyC4L13UiL_RLVSGq4qlbft6LvgHMz3g133A6E3BePWpRZ3LVGvSTln74ouL4z3eZhPESiLKtYuZMwZDNGjBSHE1534DRgzLpPg3uy_Pr4xPVtquMqR5TDKE463e71-wiY3dKkxkz79VHM3Da2TnZ3nXKgxYcLaQUjh9EGmGAbieGW5663ETaysQNEW7hHid9H4mZsCZMlTTIgcKgrds6NKnBluhVMQvDWTez88CQ_ihtVWCsJS03GRkttU1xJnDtIxhtwkY15LEuVcjpMIzruGIjOBZxPhZNWKtNbwrpjZ-Mliq_xWX09WIuROQR9fObsFrfxrihZIjKbHeANjxCcEcQtwlzhb_rXgRJFHFP4sPmXvu9-_h4fy-_WPi76SKMcSLteen3Egz3bwd2GZFNP1nJp_Abl2TxRw
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JTuQwEC0xIIa5sA0wzWoQBy5ppe0sjjQXhEDN0hxYJC4ocmxHYlEa0d1IcOIT5lvmQ-Yj5kumKhu7hOYWKWXZcbns91yVKoB1Tyg3UNp1CLw7XmgSRyrrOl5EPplEpoEiotg5DNqn3t6ZfzYEP6t_YYr8EPWFG1lGvl-TgdOF9DMr711eNHF3FeILjFBF75xQHfFnPoTCvyxc14m80C_zClEcT9305Wn0BmK-RKz5kbMzAefVYItIk6vmoJ809cOrPI7_-zWTMF5iUbZZLJ4pGLLZNIwW1Snvp-Frp_S7fwf3z--_j78ovF1lTPWYYojGWb_bvWYXGbtTmsSYeQpAmoHTne2TrbZT1lpwtJBSOH4QaUQCupUYbnnqchNpKxM3RMSFx5z0feRmwpowVdIgDQqDlm7p0KQGW6JixSwMZ93M_gCGDEhpqwJjLaVzk5HRUtsUFwPXPuLRBmxUcx7rMhE51cO4jitCgnMR53PRgLVa9KbIvvGe0GKluLg0wF7MhYg8Yn9-A1br12g65A9Rme0OUIZHiO8I5TZgrlB43YugLEXckzjYXG0fdx8f7-3mD_OfF12BsfZJ5yA-2D3cX4BvnDh8Hgm-CMP924FdQqDTT5bz9fwPsL_1Yg
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bThsxEB1BUBEvlFIuKQFM1QdeNnLsvXjFEyJEQAFVpZHygLTy2l6JizYRSZDoUz-h38KH8BH9EsZ741YkxNtKO5a9nhn7HM_sGOCbyyX1paKOBe-OG-jYEdJQxw1tTCYWiS8tUTw69ve67kHP603AVvkvTF4fojpws56RrdfWwQc6eeTkw_OzJi6unE_ClOtTYU26_ZM9CiHk4WVOqRO6gVeUFbJpPFXTp5vRC4T5FLBmO07nI5yWY80TTS6a41HcVL-flXF858fMwWyBRMl2bjqfYMKk8_Ahv5vyZh6mj4qo-2egd7f__vy1ye0yJXJIJEEsTkb9_iU5S8m1VFaM6If0owXodnZ_7ew5xU0LjuJCcMfzQ4U4QLVizQxLKNOhMiKmAeIt3OSE5yEz40YHiRQaSVDgt1RLBTrR2BLVyhehlvZTswwE-Y9URvraGFvMTYRaCWUSNAWmPESjddgspzxSRRlyexvGZVTSEZyLKJuLOnytRAd57Y3_CTVKvUWF-w0jxnnoWu7n1WGjeo2OY6MhMjX9McqwENGdxbh1WMr1XfXCbY0i5gocbKa117uPTg72s4cvbxddh-kf7U50uH_8fQVmmCXwWRp4A2qjq7FZRZQzitcya74H8ar0Gg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%CE%B2%E2%80%90glucan+as+a+new+tool+in+vaccine+development&rft.jtitle=Scandinavian+journal+of+immunology&rft.au=Vetvicka%2C+Vaclav&rft.au=Vannucci%2C+Luca&rft.au=Sima%2C+Petr&rft.date=2020-02-01&rft.issn=0300-9475&rft.eissn=1365-3083&rft.volume=91&rft.issue=2&rft.epage=n%2Fa&rft_id=info:doi/10.1111%2Fsji.12833&rft.externalDBID=10.1111%252Fsji.12833&rft.externalDocID=SJI12833
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0300-9475&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0300-9475&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0300-9475&client=summon